Goldman Sachs analyst Corinne Jenkins reiterated a Neutral rating and $5.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE